← All causality assessments
Coding artifact: the indication reported back as the "reaction"
Causality assessment · Coding artifact: the indication reported back as the "reaction"
Nirmatrelvir And Ritonavir and Covid-19: is the FAERS signal real?
A written Bradford Hill assessment of one drug–event pair. The grade is a judgement about the signal, not a statement that this drug causes this event in any one person; FAERS counts are reports, not rates.
Nirmatrelvir And Ritonavir ↔ Covid-19
n=— co-reports · PRR — · ROR —
Nirmatrelvir/ritonavir (Paxlovid) is an oral antiviral for mild-to-moderate COVID-19. Co-reporting of COVID-19 as a reaction is partly a coding artifact (indication overflow) and partly the viral rebound phenomenon. 2,588 co-reports (PRR 62.2) reflect the treated population and known rebound, not causation.
Coding artifact / rebound. Paxlovid label (no boxed warning for COVID-19). Rebound: NEJM 2022, PMID: 37596423.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | not established | Indication artifact / viral rebound |
| Strength | not established | PRR reflects treated population |
| Consistency | not established | Viral rebound documented but distinct from causation |
| Specificity | not established | Not specific |
| Biological gradient | not established | No gradient |
| Plausibility | not established | No mechanism for causing own indication |
| Coherence | not established | Coherent only as artifact |
| Experiment | n/a | EPIC trial tracked rebound |
| Analogy | not established | Not applicable |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✗ No ClinicalTrials.gov results-posting trial in the top search hits for Nirmatrelvir captured covid-19 as a tracked adverse event in a usable structure. The EPIC trial (NCT04960203) tracked COVID-19-related AEs; rebound is well-described.